Relation of dose intensity and efficacy, toxicity in paclitaxel as a single agent for advanced breast cancer / 中华肿瘤杂志
Chinese Journal of Oncology
;
(12): 56-58, 2005.
Artículo
en Chino
| WPRIM
| ID: wpr-331242
ABSTRACT
<p><b>OBJECTIVE</b>To evaluate the relation of dose intensity and efficacy, toxicity in advanced breast cancer treated with paclitaxel as a single agent.</p><p><b>METHODS</b>Seventy-one patients with advanced breast cancer received paclitaxel as a single agent with different dose intensities. According to the phase I or phase II trial, the standard dose intensity of paclitaxel was defined as 58.3 mg.(m(2))(-1).week(-1). The dose of paclitaxel was 175 mg/m(2) given every three weeks, ranging 33.3 - 70.3 mg.(m(2))(-1).week(-1) [median delivered dose intensity 58.82 mg.(m(2))(-1).week(-1)]. Efficacy and toxicity was evaluated.</p><p><b>RESULTS</b>The overall response rate in this group of advanced breast cancer was 40.8%. Responses were seen in lungs, soft tissue, bone and liver, with the response rates of 52.0%, 38.0%, 12.5%, 7.7%, respectively. When the relative dose intensity (RDI) was > 1.0, 0.9 - 1.0, < 0.9, the response rates were 44.2%, 47.6%, 0, respectively. The difference between the group (RDI >/= 0.9% - 1.0%) in 7 patients and the group (RDI < 0.9) was significant (P < 0.05). Toxicity was well tolerated, with the efficacy decreased as soon as the RDI had been reduced without embarrassing the toxicity.</p><p><b>CONCLUSION</b>Paclitaxel as a single agent therapy with standard dose intensity is effective and well tolerated by patients with advanced breast cancer.</p>
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Patología
/
Neoplasias Óseas
/
Inducción de Remisión
/
Neoplasias de la Mama
/
Paclitaxel
/
Relación Dosis-Respuesta a Droga
/
Quimioterapia
/
Leucopenia
/
Neoplasias Hepáticas
/
Estadificación de Neoplasias
Límite:
Adulto
/
Anciano
/
Femenino
/
Humanos
Idioma:
Chino
Revista:
Chinese Journal of Oncology
Año:
2005
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS